Incanthera PLC (AQSE:INC) Chairman Tim McCarthy recently presented at the Proactive One2One Investor Forum.
Focused on innovative dermatology and oncology technologies, the company was formed in 2010 as a spin-off from the University of Bradford's Institute of Cancer Therapeutics. Initially a typical non-revenue generating biotech company, it focused on developing cancer therapies and raising private and venture capital. In 2020, Incanthera listed on the Aquis Exchange.
The company has recently undergone a significant transformation due to a deal with Marionnaud, a subsidiary of AS Watson Group, the largest international health and beauty retailer. This partnership focuses on innovative drug delivery technology through skincare, allowing the application of active ingredients that repair and restore skin cells.
Incanthera's product range, branded as Skin and Cell, includes high-end skincare with scientifically proven benefits, particularly targeting the Chinese market. The first order of 25,000 units has been doubled to 50,000, with projections of 250,000 units. This deal is expected to generate significant revenue, projected at £10 million for the current year with a 30% EBITDA margin, and £33 million the next year.
Incanthera retains exclusive rights outside Europe, China, and Asia, enabling further growth. The company is now cash-generative, profitable, and plans to offer dividends. Institutional investors show increasing interest, enhancing its market profile and share value.